公开(公告)号：US20170266134A1

公开(公告)日：2017-09-21

申请号：US15310351

申请日：2015-05-12

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Antony D. LOEBEL ,  Kenneth S. KOBLAN

IPC: A61K31/135 ,  A61K9/00

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/4858

Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.

公开(公告)号：US09505751B2

公开(公告)日：2016-11-29

申请号：US14409866

申请日：2013-06-19

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： John Emmerson Campbell ,  Phillip G. Jones ,  Scott Malcolm

IPC: A61K31/4985 ,  C07D241/38 ,  C07D487/04 ,  C07D471/04 ,  A61K31/437 ,  A61K31/4709 ,  C07D519/00

CPC classification number: C07D519/00 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/4985 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are substituted triazolopyrazine phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Abstract translation: 本文提供了可用于治疗例如中枢神经系统和代谢疾病和病症的取代三唑并吡嗪磷酸二酯酶抑制剂及其药物组合物。

公开(公告)号：US09260452B2

公开(公告)日：2016-02-16

申请号：US14124455

申请日：2012-06-08

Applicant: Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

Inventor： Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

IPC: C07D471/04 ,  A61K31/519 ,  C07D498/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/04 ,  C07D487/14 ,  C07D487/18 ,  C07D491/147 ,  C07D491/20 ,  C07D491/22

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/10 ,  C07D487/14 ,  C07D487/18 ,  C07D491/147 ,  C07D491/20 ,  C07D491/22 ,  C07D498/04

Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.

Abstract translation: 公开了调节GluR5活性的化合物及其使用方法。

公开(公告)号：US09249162B2

公开(公告)日：2016-02-02

申请号：US14298691

申请日：2014-06-06

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John Emmerson Campbell ,  Philip Jones ,  Michael Charles Hewitt

IPC: A61K31/4353 ,  C07D471/04 ,  C07D519/00 ,  A61K45/06 ,  C07D487/04 ,  A61K31/4375 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5383

CPC classification number: C07D519/00 ,  A61K31/4375 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5383 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is  wherein L, B and R3 are defined herein, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds and compositions provided herein are PDE-10 inhibitors and useful, e.g., for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Abstract translation: 本文提供了式A-L-B化合物及其药学上可接受的盐和立体异构体，其中A是其中L，B和R 3在本文中定义，其合成方法，包含该化合物的药物组合物及其使用方法。 本文提供的化合物和组合物是PDE-10抑制剂，并且可用于例如治疗，预防和/或治疗各种疾病，例如CNS障碍和代谢紊乱，包括但不限于例如神经障碍， 精神病，精神分裂症，肥胖症和糖尿病。

公开(公告)号：US09072699B2

公开(公告)日：2015-07-07

申请号：US14152377

申请日：2014-01-10

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Thomas Jerussi ,  Qun Kevin Fang ,  Mark G. Currie

IPC: A61K31/135 ,  C07C211/42

CPC classification number: A61K31/135 ,  C07B2200/07 ,  C07C211/42 ,  C07C2602/10

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

公开(公告)号：US08889686B2

公开(公告)日：2014-11-18

申请号：US13932324

申请日：2013-07-01

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： H. Scott Wilkinson ,  Richard Hsia ,  Tushar Misra ,  Kostas Saranteas ,  Patrick Mousaw

IPC: A61K31/44 ,  A61K31/495 ,  A61K31/4985 ,  C07D213/61 ,  C07D295/182 ,  C07D471/04 ,  C07D487/04 ,  C07C59/245

CPC classification number: C07D487/04 ,  C07C59/245

Abstract: L malate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are disclosed for decreasing the bitterness of eszopiclone dosage forms

Abstract translation: （6-（5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰基氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4- b]吡嗪）用于降低右佐佐单抗剂型的苦味

公开(公告)号：US08809332B2

公开(公告)日：2014-08-19

申请号：US13927439

申请日：2013-06-26

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Richard Hsia ,  H. Scott Wilkinson ,  Tushar Misra ,  Kostas Saranteas ,  Patrick Mousaw

IPC: A61K31/444 ,  A61K31/495 ,  A61K31/4985 ,  C07D213/61 ,  C07D295/182 ,  C07D471/04

CPC classification number: C07D487/04

Abstract: Besylate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided.

Abstract translation: -5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4-b ]吡嗪）。

公开(公告)号：US20140221332A1

公开(公告)日：2014-08-07

申请号：US14122519

申请日：2012-05-25

Applicant: Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat

Inventor： Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat

IPC: C07D413/10 ,  C07D235/18 ,  C07D471/04 ,  C07D249/08 ,  C07D401/14 ,  C07D487/04 ,  C07D271/06 ,  C07D413/06 ,  C07D413/04 ,  C07D413/14 ,  C07D487/08 ,  C07D271/10 ,  C07D401/10

CPC classification number: C07D413/10 ,  C07D235/18 ,  C07D249/08 ,  C07D271/06 ,  C07D271/07 ,  C07D271/10 ,  C07D401/10 ,  C07D401/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.

Abstract translation: 公开了调节GluR5活性的化合物及其使用方法。

公开(公告)号：US20140179682A1

公开(公告)日：2014-06-26

申请号：US14124455

申请日：2012-06-08

Applicant: Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

Inventor： Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

IPC: C07D498/04 ,  C07D471/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/20

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/10 ,  C07D487/14 ,  C07D487/18 ,  C07D491/147 ,  C07D491/20 ,  C07D491/22 ,  C07D498/04

Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.

公开(公告)号：US20140128474A1

公开(公告)日：2014-05-08

申请号：US14152377

申请日：2014-01-10

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Thomas JERUSSI ,  Qun Kevin FANG ,  Mark G. CURRIE

IPC: A61K31/135

CPC classification number: A61K31/135 ,  C07B2200/07 ,  C07C211/42 ,  C07C2602/10

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract translation: 用（1R，4S） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理CNS病症; 和（1S，4R） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺。 还公开了制备4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺的方法。 该方法包括制备N- [4-（3,4-二氯苯基）-1,2,3,4-四氢萘-1-基]甲酰胺的全部四种异构体，它们也是有用的。